Stockreport

Alzamend Neuro Reports Second Quarter 2025 Financial Results and Provides Update on Clinical Programs

Alzamend Neuro, Inc.  (ALZN) 
PDF During the six months ended October 31, 2024, net cash provided by financing activities was $8.3 millionStockholder equity of $3.8 million at October 31, 2024, including [Read more]